JP2007511474A5 - - Google Patents

Download PDF

Info

Publication number
JP2007511474A5
JP2007511474A5 JP2006536050A JP2006536050A JP2007511474A5 JP 2007511474 A5 JP2007511474 A5 JP 2007511474A5 JP 2006536050 A JP2006536050 A JP 2006536050A JP 2006536050 A JP2006536050 A JP 2006536050A JP 2007511474 A5 JP2007511474 A5 JP 2007511474A5
Authority
JP
Japan
Prior art keywords
modulator
protein
pharmaceutical composition
composition according
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006536050A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007511474A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2004/011926 external-priority patent/WO2005039635A2/en
Publication of JP2007511474A publication Critical patent/JP2007511474A/ja
Publication of JP2007511474A5 publication Critical patent/JP2007511474A5/ja
Pending legal-status Critical Current

Links

JP2006536050A 2003-10-22 2004-10-21 神経変性障害に関与する遺伝子 Pending JP2007511474A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51324103P 2003-10-22 2003-10-22
PCT/EP2004/011926 WO2005039635A2 (en) 2003-10-22 2004-10-21 Genes involved in neurodegenerative disorders

Publications (2)

Publication Number Publication Date
JP2007511474A JP2007511474A (ja) 2007-05-10
JP2007511474A5 true JP2007511474A5 (https=) 2007-12-06

Family

ID=34520083

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006536050A Pending JP2007511474A (ja) 2003-10-22 2004-10-21 神経変性障害に関与する遺伝子

Country Status (4)

Country Link
US (1) US20090016963A1 (https=)
EP (1) EP1678326A2 (https=)
JP (1) JP2007511474A (https=)
WO (1) WO2005039635A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1859274A2 (en) * 2005-03-07 2007-11-28 Novartis AG Genes involved in neurodegenerative conditions
JP4191189B2 (ja) * 2005-12-08 2008-12-03 康生 梅津 がん関連遺伝子活性化能を有するペプチド
ES2310434B1 (es) * 2006-01-19 2009-11-12 Consejo Superior Investig. Cientificas Un pmto de identificacion de un proceso de fibrosis renal, pmto de identificacion de compuestos inhibidores, uso de los compuestos inhibidores de la expresion del gen del factor de transcripcion snail en la elaboracion de composiciones farmaceuticas, dichas composiciones.....
JP5451376B2 (ja) * 2007-03-15 2014-03-26 株式会社リバース・プロテオミクス研究所 血球系に特異的あるいは破骨細胞分化に特異的なバイオマーカー
US8153764B2 (en) 2007-03-15 2012-04-10 Reverse Proteomics Research Institute Co., Ltd. Biomarker specific to brain/nerve or specific to neuronal differentiation
EP3915552A1 (en) * 2015-06-01 2021-12-01 Xeno Biosciences Inc. Compositions for use in modulating the gut microbiota and managing weight
CN109298186A (zh) * 2018-09-29 2019-02-01 安徽科技学院 一种基于碳纳米管和三螺旋分子开关的试纸条生物传感器及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7129700A (en) * 1999-09-10 2001-04-10 Corixa Corporation Ovarian tumor sequences and methods of use therefor
US6900367B2 (en) * 2000-09-29 2005-05-31 Novartis Transgenic Drosophila melanogaster expressing a β42 in the eye
WO2002057496A2 (en) * 2001-01-18 2002-07-25 Socratech L.L.C. Gene expression profiling of endothelium in alzheimer's disease
AU2003214048A1 (en) * 2002-01-25 2003-09-02 Develogen Aktiengesellschaft Fur Entwicklungsbiologische Forschung Proteins involved in the regulation of energy homeostasis and organelle metabolism

Similar Documents

Publication Publication Date Title
JP5770472B2 (ja) ヒト急性白血病におけるｅｐｈａ７及びｅｒｋリン酸化の調節解除を誘発するための方法及び組成物
AU2009285644B2 (en) Markers and methods for assessing and treating ulcerative colitis and related disorders using a 20 gene panel
US20120065148A1 (en) Phosphodiesterase 4d7 as prostate cancer marker
JP2007506426A5 (https=)
WO2009075579A1 (en) Biomarkers for cardiovascular disease
CN115175685B (zh) 用于治疗血管生成素样4(angptl4)相关疾病的寡核苷酸
JP2009502115A5 (https=)
CN110791560A (zh) 一种用于阿尔茨海默病诊断和/或治疗的miRNA标志物
JP2008118915A (ja) 胃癌高発現遺伝子特定による胃癌診断および創薬への利用
EP1838875A2 (en) Compositions and methods for modulating gene expression using self-protected oligonucleotides
JP5918694B2 (ja) 前立腺がんのマーカーとしてのホスホジエステラーゼ９ａ
JP2006508642A (ja) 脂肪の蓄積を減少させる方法と、関連疾患を治療するための方法
JP2007511474A5 (https=)
KR20180109811A (ko) 항암 치료 내성 판단 방법 및 상기 방법에 사용되는 조성물
US20110236396A1 (en) Methods and compositions for diagnosing and treating a colorectal adenocarcinoma
US20240247264A1 (en) NOVEL lncRNA CONTROLLING CARDIAC FIBROSIS
US20050009030A1 (en) Histone deacetylase: novel molecular target of neurotoxicity
’t Hoen et al. Gene expression profiling to monitor therapeutic and adverse effects of antisense therapies for Duchenne muscular dystrophy
US20130102028A1 (en) Cartilage-specific hif-2alpha transgenic mouse as an animal model for arthritis, and use thereof
JP2009523004A5 (https=)
EP2148943B1 (en) Methods for assessing and treating ulcerative colitis and related disorders using a 19 gene panel
KR101466661B1 (ko) Ｔｍｃ５ 유전자의 신규한 용도
JPWO2022064198A5 (https=)
WO2025184324A1 (en) Methods and compositions for prognosis and treatment of cancer therapy-related cardiac dysfunction
JPWO2020191163A5 (https=)